Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study
Abstract Background To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (hereafter, TACE-RFA) in treating Barcelona Clinic Liver Cancer (BCLC) Stage A or B (hereafter, BCLC A/B) hepatocellular carcinoma (HCC) patients, and to explore t...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-10-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-019-6237-5 |
| _version_ | 1818460108421595136 |
|---|---|
| author | Yanqiao Ren Yanyan Cao Hong Ma Xuefeng Kan Chen Zhou Jiacheng Liu Qin Shi Gansheng Feng Bin Xiong Chuansheng Zheng |
| author_facet | Yanqiao Ren Yanyan Cao Hong Ma Xuefeng Kan Chen Zhou Jiacheng Liu Qin Shi Gansheng Feng Bin Xiong Chuansheng Zheng |
| author_sort | Yanqiao Ren |
| collection | DOAJ |
| description | Abstract Background To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (hereafter, TACE-RFA) in treating Barcelona Clinic Liver Cancer (BCLC) Stage A or B (hereafter, BCLC A/B) hepatocellular carcinoma (HCC) patients, and to explore the range of tumor sizes suitable for combination therapy. Methods This retrospective study assessed the consecutive medical records of HCC patients with BCLC A/B who received TACE-RFA or TACE from September 2009 to September 2018. Progression-free survival (PFS), overall survival (OS), therapeutic response, and complications were compared between the two groups. Results Among 2447 patients who received TACE-RFA or TACE, 399 eligible patients were enrolled in our study, including 128 patients in the TACE-RFA group and 271 patients in the TACE group. Compared with the TACE group, the PFS and OS rates of 1,3,5,8 years in the TACE-RFA group were significantly better, with higher objective tumor regression rate and better disease control rate. RFA treatment did not increase the risk of death in patients with HCC, and both liver subcapsular hematoma and bile duct injury were improved by symptomatic treatment. Serum α-fetoprotein level and treatment method were important independent prognostic factors for OS, whereas albumin, hepatitis B and treatment method were important independent prognostic factors for PFS. Subgroup analysis showed that patients in the TACE-RFA group always showed better OS and PFS. Conclusions TACE-RFA had an advantage over TACE alone in prolonging PFS and improving OS in HCC patients with BCLC A/B, and can benefit patients regardless of tumor size. |
| first_indexed | 2024-12-14T23:25:00Z |
| format | Article |
| id | doaj.art-994422801357463798bfacac0304d5a4 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-14T23:25:00Z |
| publishDate | 2019-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-994422801357463798bfacac0304d5a42022-12-21T22:43:50ZengBMCBMC Cancer1471-24072019-10-0119111010.1186/s12885-019-6237-5Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control studyYanqiao Ren0Yanyan Cao1Hong Ma2Xuefeng Kan3Chen Zhou4Jiacheng Liu5Qin Shi6Gansheng Feng7Bin Xiong8Chuansheng Zheng9Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Background To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (hereafter, TACE-RFA) in treating Barcelona Clinic Liver Cancer (BCLC) Stage A or B (hereafter, BCLC A/B) hepatocellular carcinoma (HCC) patients, and to explore the range of tumor sizes suitable for combination therapy. Methods This retrospective study assessed the consecutive medical records of HCC patients with BCLC A/B who received TACE-RFA or TACE from September 2009 to September 2018. Progression-free survival (PFS), overall survival (OS), therapeutic response, and complications were compared between the two groups. Results Among 2447 patients who received TACE-RFA or TACE, 399 eligible patients were enrolled in our study, including 128 patients in the TACE-RFA group and 271 patients in the TACE group. Compared with the TACE group, the PFS and OS rates of 1,3,5,8 years in the TACE-RFA group were significantly better, with higher objective tumor regression rate and better disease control rate. RFA treatment did not increase the risk of death in patients with HCC, and both liver subcapsular hematoma and bile duct injury were improved by symptomatic treatment. Serum α-fetoprotein level and treatment method were important independent prognostic factors for OS, whereas albumin, hepatitis B and treatment method were important independent prognostic factors for PFS. Subgroup analysis showed that patients in the TACE-RFA group always showed better OS and PFS. Conclusions TACE-RFA had an advantage over TACE alone in prolonging PFS and improving OS in HCC patients with BCLC A/B, and can benefit patients regardless of tumor size.http://link.springer.com/article/10.1186/s12885-019-6237-5ChemoembolizationTherapeuticRadiofrequency ablationHepatocellular carcinoma |
| spellingShingle | Yanqiao Ren Yanyan Cao Hong Ma Xuefeng Kan Chen Zhou Jiacheng Liu Qin Shi Gansheng Feng Bin Xiong Chuansheng Zheng Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study BMC Cancer Chemoembolization Therapeutic Radiofrequency ablation Hepatocellular carcinoma |
| title | Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study |
| title_full | Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study |
| title_fullStr | Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study |
| title_full_unstemmed | Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study |
| title_short | Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study |
| title_sort | improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in barcelona clinic liver cancer stage a or b hepatocellular carcinoma regardless of tumor size results of a single center retrospective case control study |
| topic | Chemoembolization Therapeutic Radiofrequency ablation Hepatocellular carcinoma |
| url | http://link.springer.com/article/10.1186/s12885-019-6237-5 |
| work_keys_str_mv | AT yanqiaoren improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy AT yanyancao improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy AT hongma improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy AT xuefengkan improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy AT chenzhou improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy AT jiachengliu improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy AT qinshi improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy AT ganshengfeng improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy AT binxiong improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy AT chuanshengzheng improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy |